{
  "company": "CIPLA",
  "report_date": "October 26, 2021",
  "filename": "CIPLA_transcript_Oct_2021.pdf",
  "quarter": "Q2",
  "fiscal_year": "2022",
  "management_team": [
    "MR. UMANG VOHRA - MANAGING DIRECTOR &",
    "MR. KEDAR UPADHYE - GLOBAL CHIEF FINANCIAL",
    "MR. NAVEEN BANSAL - HEAD, INVESTOR RELATIONS,",
    "UMANG VOHRA - MANAGING DIRECTOR &",
    "KEDAR UPADHYE - GLOBAL CHIEF FINANCIAL",
    "NAVEEN BANSAL - HEAD, INVESTOR RELATIONS,"
  ],
  "moderator": "MR",
  "analysts": [
    {
      "name": "Prakash",
      "firm": "Axis Capital"
    },
    {
      "name": "Tushar Manudhane",
      "firm": "Motilal Oswal \nFinancial Services"
    },
    {
      "name": "Foram Parekh",
      "firm": "Choice Institutional \nBroking"
    },
    {
      "name": "Anubhav Agarwal",
      "firm": "Credit Suisse"
    },
    {
      "name": "Kunal Damesha",
      "firm": "Emkay Global"
    },
    {
      "name": "Surya Patra",
      "firm": "Philip Capital"
    },
    {
      "name": "Nitya Balasubramayam",
      "firm": "Bernstein \nResearch"
    },
    {
      "name": "Nitin Agarwal",
      "firm": "DAM Capital"
    },
    {
      "name": "Charulata Gaidhani",
      "firm": "Dalal & Broacha"
    },
    {
      "name": "Sameer Baisiwala",
      "firm": "Morgan Stanley"
    }
  ],
  "qa_segments": [],
  "key_financial_metrics": {
    "sales_inr_crores": "1279",
    "growth_percentage": "22",
    "increase_percentage": "3",
    "ebitda_margin_percentage": "22",
    "ebitda_inr_crores": "1226"
  },
  "business_highlights": [
    "partnerships with several MNC organizations \nfor the strategic widening of our therapy base with specialty offerings across cardiology, anti-\ndiabetic, oncology franchise.",
    "partnership with Eli Lily for \nthe diabetes franchise."
  ],
  "extraction_metadata": {
    "extraction_date": "2025-08-03T01:08:55.584304",
    "source_file": "data\\cipla\\CIPLA_transcript_Oct_2021.pdf",
    "text_length": 52770,
    "extraction_method": "PyMuPDF + Regex parsing + Filename analysis"
  }
}